Gilead Sciences | Kapitał Własny I Rezerwy



Equity Capital And Reserves Zmiana Data
AbbVie USD 3.32B 2.71B 2024-12
Agios Pharmaceuticals USD 1.54B 85.72M 2024-12
ALKERMES USD 1.46B 172.88M 2024-12
Alnylam Pharmaceuticals USD 67.09M 34.73M 2024-12
Amgen USD 5.88B 1.65B 2024-12
Biogen USD 16.72B 357.1M 2024-12
BioMarin Pharmaceutical USD 5.66B 244.59M 2024-12
Bristol-Myers Squibb USD 16.34B 807M 2024-12
Eli Lilly USD 14.19B 47.9M 2024-12
Gilead Sciences USD 19.33B 856M 2024-12
GlaxoSmithKline GBP 13.67B 218M 2024-12
Glaxosmithkline GBP 13.67B 337M 2024-12
Incyte USD 3.45B 276.41M 2024-12
J&J USD 71.49B 1.33B 2024-12
Merck USD 46.31B 1.81B 2024-12
Moderna USD 10.9B 1.03B 2024-12
Neurocrine Biosciences USD 2.59B 129.2M 2024-12
Novartis USD 44.05B 605M 2024-12
Pfizer USD 88.2B 4.08B 2024-12
PTC Therapeutics USD -1098071000 43.72M 2024-12
Regeneron Pharmaceuticals USD 29.35B 27.7M 2024-12
Sanofi 73B 1.36B 2024-06
Sarepta Therapeutics USD 1.53B 306.67M 2024-12
United Therapeutics USD 6.44B 343.1M 2024-12
Vertex Pharmaceuticals USD 16.41B 778.7M 2024-12



Gilead Sciences Kapitał Własny I Rezerwy - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.